Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | N/A |
| 52 Week High | $101.89 |
| 52 Week Low | $25.35 |
| Target Price | $100.00 |
| Ticker | PRNB:UW |
| Composite Ticker | PRNB:US |
| Security Name | Principia Biopharma Inc |
| Type | Ordinary Shares |
| Class | PRNB |
| Currency | USD |
| Round Lot Size | N/A |
| Primary | Yes |
| Delisted | Yes |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG00LQM9G47 |
| Composite FIGI | BBG0026ZK3M8 |
| Share Class FIGI | BBG0026ZK3N7 |
| FIGI Unique ID | EQ0000000020622227 |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | N/A |
| Beta | 1.3223 |
| 1-year beta | 1.1947 |
| 3-year beta | 1.3223 |
| 5-year beta | 1.3223 |
| 7-year beta | 1.3223 |
| 10-year beta | 1.3223 |
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
